CYP2D6-mediated catalysis of tamoxifen aromatic hydroxylation with an NIH shift: similar hydroxylation mechanism in chicken, rat and human liver microsomes

References

• ALBERG A. J., LAM, A. P. and HELZLSOUER, K. J., 1999, Epidemiology, prevention, and early detection of breast cancer. Current Opinions in Oncology, 11, 435–441.
   Google Scholar
• BOOCOCK, D. J., MAGGS, J. L., WHITE, I. N. and PARK, B. K., 1999, Alpha-hydroxytamoxifen, a genotoxic metabolite of tamoxifen in the rat: identification and quantification in vivo and in vitro. Carcinogenesis, 20, 153–160.
   PubMed Web of Science ®Google Scholar
• BORGNA, J. L. and ROCHEFORT, H., 1981, Hydroxylated metabolites of tamoxifen are formed in vivo and bound to estrogen receptor in target tissues. Journal of Biological Chemistry, 256, 859–868.
   PubMed Web of Science ®Google Scholar
• BURSTEIN, S. H. and KUPFER, D., 1971, Hydroxylation of trans Al-tetrahydrocannabinol by hepatic microsomal oxygenase. Annals of the New York Academy of Sciences, 191, 61–67.
   Web of Science ®Google Scholar
• CHLEBOWSKI, R. J., BUTLER, J., NELSON, A. and LILLINGTON, L., 1993, Breast cancer chemoprevention. Tamoxifen: current issues and future perspective. Cancer, 72, 1032–1037.
   PubMed Web of Science ®Google Scholar
• CREWE, H. K., ELLIS, S. W., LENNARD, M. S. and TUCKER, G. T., 1997, Variable contribution of cytochromes P450 2D6, 2C9 &3A4 to 4-hydroxylation of tamoxifen in human liver microsomes. Biochemical Pharmacology, 53, 171–178.
   PubMed Web of Science ®Google Scholar
• DEHAL, S. S. and KUPFER, D., 1996, Evidence that the catechol 3, 4 dihydroxytamoxifen is a proximate intermediate to the reactive species binding covalently to proteins. Cancer Research, 56, 1283–1290.
   PubMed Web of Science ®Google Scholar
• DEHAL, S. S. and KUPFER, D., 1997, CYP2D6 catalyzes tamoxifen 4-hydroxylation in human liver. Cancer Research, 57, 3402–3406.
   PubMed Web of Science ®Google Scholar
• DEHAL, S. S., RICHARDSON, T. H., JOHNSON, E. F. and KUPFER, D., 1996, CYP2D6 catalyzes tamoxifen 4-hydroxylation in human liver. In Proceedings of the XIth International Symposium on Microsomes and Drug Oxidations, Los Angeles, CA, USA, p. 71.
   Google Scholar
• FORTE, A. J., WILSON, J. M., SLATTERY, J. T. and NELSON, S. D., 1984, The formation of catechol metabolites of acetaminophen in mice. Drug Metabolism and Disposition, 12, 484–491.
   PubMed Web of Science ®Google Scholar
• FOSTER, A. B., GRIGGS, L. J., JARMAN, M., VANMAANEN, M. S. and SCHULTEN, H.-R., 1980, Metabolism of tamoxifen by rat liver microsomes: formation of the oxide, a new metabolite. Biochemical Pharmacology, 9, 1977–1979.
   Google Scholar
• FROMSON, J. M., PEARSON, S. and BRAMAH, S., 1973a, The metabolism of tamoxifen (I.C.I. 46,474). I. In laboratory animals. Xenobiotica, 11, 693–709.
   Web of Science ®Google Scholar
• FROMSON, J. M., PEARSON, 5, and BRAMAH, S., 1973b, The metabolism of tamoxifen (I.C.I. 46, 474). II. In female patients. Xenobiotica, 11, 711–714.
   Google Scholar
• FURR, B. J. A. and JORDAN, V. C., 1984, The pharmacology and clinical uses of tamoxifen. Pharmacology and Therapeutics, 25, 127–205.
   Google Scholar
• GUROFF, G., DALY, J. W., JERINA, D. M., RENSON, J., WITKOP, B. and UDENFRIEND, S., 1967, Hydroxylation-induced migration: the NIH shift. Recent experiments reveal an unexpected and general result of enzymatic hydroxylation of aromatic compounds. Science, 29, 1524–1530.
   Google Scholar
• HARDCASTLE, I. R., ROWLANDS, M. G., HOUGHTON, J., PARR, I. B., POTTER, G. A., JARMAN, M., EDWARDS, K. J., LAUGHTON, C. A., TRENT, J. O. and NEIDLE, S., 1995, Rationally designed analogs of tamoxifen with improved calmodulin antagonism. Journal of Medicinal Chemistry, 38, 241–248.
   PubMed Web of Science ®Google Scholar
• JERINA, D. M., DALY, J. W. and WITKOP, B., 1971, Migration of substituents during Hydroxylation of aromatic substrates (NIH shift). Oxidations with peroxytrifiuoroacetic acid. Biochemistry, 10, 366–372.
   PubMed Web of Science ®Google Scholar
• JORDAN, V. C., 1995, An overview of considerations for the testing of tamoxifen as a preventive for breast cancer. Annals of the New York Academy of Sciences, 768, 141–147.
   PubMed Web of Science ®Google Scholar
• KOERTS, J., SOFFERS, A. E., VERVOORT, J., DE JAGER, A. and RIETJENS, I. M., 1998, Occurrence of the NIH shift upon the cytochrome P450-catalyzed in vivo and in vitro aromatic ring hydroxylation of fiuorobenzenes. Chemical Research in Toxicology, 11, 503–512.
   PubMed Web of Science ®Google Scholar
• KUPFER, D., MANI, C., LEE, C. A. and RIFKIND, A. B., 1994, Induction of tamoxifen-4-hydroxylation by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), b-naphthofiavone (bNF), and phenobarbital (PB) in avian liver: identification of P450 TCDD AA as catalyst of 4-hydroxylation induced by TCDD and bNF. Cancer Research, 54, 3140–3144.
   PubMed Web of Science ®Google Scholar
• KUPFER, D., MIRANDA, G. M. and BULGER, W. H., 1981, A facile assay for 2-hydroxylation of estradiol by liver microsomes. Analytical Biochemistry, 116, 27–34.
   PubMed Web of Science ®Google Scholar
• LYMAN, S. D. and JORDAN, V. C., 1986, Metabolism of non-steroidal antiestrogens. In V. C. Jordan (ed.), EstrogenlAntiestrogen Action and Breast Cancer Therapy (Madison: University of Wisconsin Press), pp. 191–219.
   Google Scholar
• MANI, C., GELBOIN, H. V., PARK, S. S., PIERCE, R., PARKINSON, A. and KUPFER, D., 1993a, Metabolism of the antimammary cancer antiestrogenic agent tamoxifen. I. Cytochrome P-450-catalyzed N-demethylation and 4-hydroxylation. Drug Metabolism and Disposition, 21, 645–656.
   PubMed Web of Science ®Google Scholar
• MANI, C., HODGSON, E. and KUPFER, D., 1993b, Metabolism of the antimammary cancer antiestrogenic agent tamoxifen. II. Flavin-containing monooxygenase-mediated N-oxidation. Drug Metabolism and Disposition, 21, 657–661.
   PubMed Web of Science ®Google Scholar
• MAREZ, D., LEGRAND, M., SABBAGH, N., GUIDICE, J. M., SPIRE, C., LATTE, J. J., MEYER, U. A. and BADLY, F., 1997, Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolution. Pharmacogenetics, 7, 193–202.
   PubMedGoogle Scholar
• MCCAGUE, R. and SEAGO, A., 1986, Aspects of metabolism of tamoxifen by rat liver microsomes. Identification of a new metabolite: E-1-[4-(2-dimethyl aminoethoxy)-phenyl]-1,2-dipheny1-1-buten-3-ol -N-oxide. Biochemical Pharmacology, 35, 827–834.
   PubMed Web of Science ®Google Scholar
• MCCAGUE, R., LECLERCQ, G., LEGROS, N., GOODMAN, J., BLACKBURN, G., FOSTER, M. and ALLAN, B., 1989, Derivatives of tamoxifen. Dependence of antiestrogenicity on the 4-substituent. Journal of Medicinal Chemistry, 32, 2527–2533.
   PubMed Web of Science ®Google Scholar
• REINHOLD, V. N. and BRUNI, R. J., 1976, Aromatic hydroxylation of ellipticine in rats: lack of an NIH shift. Biomedical Mass Spectrometry, 3, 335–339.
   PubMedGoogle Scholar
• REUNITZ, P. C., BAGLEY, J. R. and PAPE, C. W., 1984, Some chemical and biochemical aspects of liver microsomal metabolism of tamoxifen. Drug Metabolism and Disposition, 12, 478–483.
   PubMed Web of Science ®Google Scholar
• WIBERG, K. B., 1955, The deuterium isotope effect. Chemical Reviews, 55, 713–743.
   Web of Science ®Google Scholar
• YANKWICH, P. E., 1953, Isotope effects in chemical reactions. Annual Review of Nuclear Science, 3, 235–248.
   Google Scholar